Funded Tech Companies
Shinobi Therapeutics
Headquartered in San Francisco, Shinobi Therapeutics has funding from Astellas Venture Capital, D3 and Fast Track Initiative.
Company Overview
Company Name
Shinobi Therapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Undisclosed
San Francisco, CA Undisclosed
USA
San Francisco, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs. Shinobi uses the world's most comprehensive immune evasion technology to unlock the full potential of iPSCs. This is Shinobi, the first iPS cell therapy compatible with the patient's immune system. Shinobi's comprehensive immune evasion technology not only shields against T-cells and innate immunity, but also against antibody-mediated rejection.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
12/12/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Kemp
Co-Founder
Tobias Deuse
Co-Founder
Shin Kaneko
Company Investors
- Astellas Venture Capital
- D3
- Fast Track Initiative
- F-Prime Capital
- JIC Venture Growth Investments
- EQT Life Sciences
- Eight Roads
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
The company data above is provided by VentureDeal.com, a leading supplier of venture capital funding data.
Additional Resources for Entrepreneurs